We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$357M
Cap. Flow
+$1.29M
Cap. Flow %
0.04%
Top 10 Hldgs %
74.76%
Holding
30
New
1
Increased
13
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$32.1M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$24.6M
3
RDUS
Radius Health, Inc.
RDUS
+$7.55M
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$6.76M
5
MGNX icon
MacroGenics
MGNX
+$6.56M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$49.7M
2
TSRO
TESARO, Inc.
TSRO
+$24.4M
3
CELG
Celgene Corp
CELG
+$14.4M
4
KITE
Kite Pharma, Inc.
KITE
+$3.71M
5
SAGE
Sage Therapeutics
SAGE
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 90.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
26
Novavax
NVAX
$1.31B
$10.7M 0.35%
416,500
– –
PBYI icon
27
Puma Biotechnology
PBYI
$454M
$9.14M 0.3%
245,616
+3,625
+1% +$132K
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$8.14M 0.27%
52,191
– –
PTCT icon
29
PTC Therapeutics
PTCT
$6.12B
$6.72M 0.22%
682,912
– –
ACHN
30
DELISTED
Achillion Pharmaceuticals
ACHN
$5.39M 0.18%
1,279,340
– –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2017 Portfolio in Review

As of Q1 2017, BB Biotech held 30 positions worth $3.06B, up 13% from $2.7B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Trading was light in Q1 2017: portfolio turnover was 3.3%. BB Biotech opened 1 new position and made no exits, leaving the 30-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier.

  • BB Biotech's largest Q1 2017 buy was Five Prime Therapeutics, Inc.: 727,500 shares worth $26.3M.
  • BB Biotech added most to Ionis Pharmaceuticals in Q1 2017, an estimated $24.6M increase.
  • BB Biotech's biggest Q1 2017 reduction was Incyte, cutting an estimated $49.7M.
  • BB Biotech's ten largest holdings make up 75% of its $3.06B portfolio in Q1 2017.
  • BB Biotech opened 1 new position and closed 0 in Q1 2017.
  • BB Biotech's portfolio value rose 13% quarter-over-quarter to $3.06B.

Based on BB Biotech's 13F filing for Q1 2017, filed 10 May 2017.